{"meta":{"version":1,"warehouse":"4.0.2"},"models":{"Asset":[{"_id":"themes/landscape/source/css/style.styl","path":"css/style.styl","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/blank.gif","path":"fancybox/blank.gif","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/fancybox_loading.gif","path":"fancybox/fancybox_loading.gif","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/fancybox_loading@2x.gif","path":"fancybox/fancybox_loading@2x.gif","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/fancybox_overlay.png","path":"fancybox/fancybox_overlay.png","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/fancybox_sprite.png","path":"fancybox/fancybox_sprite.png","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/fancybox_sprite@2x.png","path":"fancybox/fancybox_sprite@2x.png","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/jquery.fancybox.css","path":"fancybox/jquery.fancybox.css","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/jquery.fancybox.js","path":"fancybox/jquery.fancybox.js","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/jquery.fancybox.pack.js","path":"fancybox/jquery.fancybox.pack.js","modified":1,"renderable":1},{"_id":"themes/landscape/source/js/script.js","path":"js/script.js","modified":1,"renderable":1},{"_id":"themes/landscape/source/css/fonts/FontAwesome.otf","path":"css/fonts/FontAwesome.otf","modified":1,"renderable":1},{"_id":"themes/landscape/source/css/fonts/fontawesome-webfont.eot","path":"css/fonts/fontawesome-webfont.eot","modified":1,"renderable":1},{"_id":"themes/landscape/source/css/fonts/fontawesome-webfont.svg","path":"css/fonts/fontawesome-webfont.svg","modified":1,"renderable":1},{"_id":"themes/landscape/source/css/fonts/fontawesome-webfont.ttf","path":"css/fonts/fontawesome-webfont.ttf","modified":1,"renderable":1},{"_id":"themes/landscape/source/css/fonts/fontawesome-webfont.woff","path":"css/fonts/fontawesome-webfont.woff","modified":1,"renderable":1},{"_id":"themes/landscape/source/css/images/banner.jpg","path":"css/images/banner.jpg","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/helpers/fancybox_buttons.png","path":"fancybox/helpers/fancybox_buttons.png","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-buttons.css","path":"fancybox/helpers/jquery.fancybox-buttons.css","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-buttons.js","path":"fancybox/helpers/jquery.fancybox-buttons.js","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-media.js","path":"fancybox/helpers/jquery.fancybox-media.js","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-thumbs.css","path":"fancybox/helpers/jquery.fancybox-thumbs.css","modified":1,"renderable":1},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-thumbs.js","path":"fancybox/helpers/jquery.fancybox-thumbs.js","modified":1,"renderable":1}],"Cache":[{"_id":"source/.DS_Store","hash":"fb7a7c368258ef94df3a3b57cbd282e368260cec","modified":1672300972264},{"_id":"source/_posts/.DS_Store","hash":"df2fbeb1400acda0909a32c1cf6bf492f1121e07","modified":1672300977271},{"_id":"source/_posts/药物前药、中间体和代谢产物的专利问题.md","hash":"7922fb70b9e85dbcfc3504756ae33d5c33afdcd9","modified":1661507173152},{"_id":"themes/landscape/.npmignore","hash":"58d26d4b5f2f94c2d02a4e4a448088e4a2527c77","modified":1671532297759},{"_id":"themes/landscape/Gruntfile.js","hash":"71adaeaac1f3cc56e36c49d549b8d8a72235c9b9","modified":1671532297760},{"_id":"themes/landscape/LICENSE","hash":"c480fce396b23997ee23cc535518ffaaf7f458f8","modified":1671532297760},{"_id":"themes/landscape/README.md","hash":"37fae88639ef60d63bd0de22314d7cc4c5d94b07","modified":1671532297759},{"_id":"themes/landscape/_config.yml","hash":"79ac6b9ed6a4de5a21ea53fc3f5a3de92e2475ff","modified":1671532297760},{"_id":"themes/landscape/package.json","hash":"544f21a0b2c7034998b36ae94dba6e3e0f39f228","modified":1671532297760},{"_id":"themes/landscape/languages/de.yml","hash":"3ebf0775abbee928c8d7bda943c191d166ded0d3","modified":1671532297760},{"_id":"themes/landscape/languages/default.yml","hash":"3083f319b352d21d80fc5e20113ddf27889c9d11","modified":1671532297760},{"_id":"themes/landscape/languages/fr.yml","hash":"415e1c580ced8e4ce20b3b0aeedc3610341c76fb","modified":1671532297760},{"_id":"themes/landscape/languages/es.yml","hash":"76edb1171b86532ef12cfd15f5f2c1ac3949f061","modified":1671532297760},{"_id":"themes/landscape/languages/ja.yml","hash":"a73e1b9c80fd6e930e2628b393bfe3fb716a21a9","modified":1671532297761},{"_id":"themes/landscape/languages/nl.yml","hash":"12ed59faba1fc4e8cdd1d42ab55ef518dde8039c","modified":1671532297761},{"_id":"themes/landscape/languages/no.yml","hash":"965a171e70347215ec726952e63f5b47930931ef","modified":1671532297761},{"_id":"themes/landscape/languages/ko.yml","hash":"881d6a0a101706e0452af81c580218e0bfddd9cf","modified":1671532297760},{"_id":"themes/landscape/languages/pt.yml","hash":"57d07b75d434fbfc33b0ddb543021cb5f53318a8","modified":1671532297761},{"_id":"themes/landscape/languages/zh-CN.yml","hash":"ca40697097ab0b3672a80b455d3f4081292d1eed","modified":1671532297761},{"_id":"themes/landscape/layout/archive.ejs","hash":"2703b07cc8ac64ae46d1d263f4653013c7e1666b","modified":1671532297760},{"_id":"themes/landscape/languages/zh-TW.yml","hash":"53ce3000c5f767759c7d2c4efcaa9049788599c3","modified":1671532297761},{"_id":"themes/landscape/layout/index.ejs","hash":"aa1b4456907bdb43e629be3931547e2d29ac58c8","modified":1671532297760},{"_id":"themes/landscape/layout/layout.ejs","hash":"f155824ca6130080bb057fa3e868a743c69c4cf5","modified":1671532297760},{"_id":"themes/landscape/scripts/fancybox.js","hash":"aa411cd072399df1ddc8e2181a3204678a5177d9","modified":1671532297760},{"_id":"themes/landscape/layout/post.ejs","hash":"7d80e4e36b14d30a7cd2ac1f61376d9ebf264e8b","modified":1671532297761},{"_id":"themes/landscape/layout/page.ejs","hash":"7d80e4e36b14d30a7cd2ac1f61376d9ebf264e8b","modified":1671532297760},{"_id":"themes/landscape/layout/tag.ejs","hash":"eaa7b4ccb2ca7befb90142e4e68995fb1ea68b2e","modified":1671532297760},{"_id":"themes/landscape/layout/category.ejs","hash":"765426a9c8236828dc34759e604cc2c52292835a","modified":1671532297760},{"_id":"themes/landscape/languages/ru.yml","hash":"4fda301bbd8b39f2c714e2c934eccc4b27c0a2b0","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/after-footer.ejs","hash":"d0d753d39038284d52b10e5075979cc97db9cd20","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/gauges-analytics.ejs","hash":"aad6312ac197d6c5aaf2104ac863d7eba46b772a","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/archive.ejs","hash":"950ddd91db8718153b329b96dc14439ab8463ba5","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/footer.ejs","hash":"93518893cf91287e797ebac543c560e2a63b8d0e","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/google-analytics.ejs","hash":"f921e7f9223d7c95165e0f835f353b2938e40c45","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/head.ejs","hash":"5abf77aec957d9445fc71a8310252f0013c84578","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/header.ejs","hash":"7e749050be126eadbc42decfbea75124ae430413","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/mobile-nav.ejs","hash":"e952a532dfc583930a666b9d4479c32d4a84b44e","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/article.ejs","hash":"c4c835615d96a950d51fa2c3b5d64d0596534fed","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/sidebar.ejs","hash":"930da35cc2d447a92e5ee8f835735e6fd2232469","modified":1671532297761},{"_id":"themes/landscape/layout/_widget/archive.ejs","hash":"beb4a86fcc82a9bdda9289b59db5a1988918bec3","modified":1671532297761},{"_id":"themes/landscape/layout/_widget/recent_posts.ejs","hash":"0d4f064733f8b9e45c0ce131fe4a689d570c883a","modified":1671532297761},{"_id":"themes/landscape/layout/_widget/category.ejs","hash":"dd1e5af3c6af3f5d6c85dfd5ca1766faed6a0b05","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/post/category.ejs","hash":"c6bcd0e04271ffca81da25bcff5adf3d46f02fc0","modified":1671532297761},{"_id":"themes/landscape/layout/_widget/tag.ejs","hash":"2de380865df9ab5f577f7d3bcadf44261eb5faae","modified":1671532297761},{"_id":"themes/landscape/layout/_widget/tagcloud.ejs","hash":"b4a2079101643f63993dcdb32925c9b071763b46","modified":1671532297761},{"_id":"themes/landscape/layout/_partial/post/date.ejs","hash":"6197802873157656e3077c5099a7dda3d3b01c29","modified":1671532297762},{"_id":"themes/landscape/layout/_partial/post/nav.ejs","hash":"16a904de7bceccbb36b4267565f2215704db2880","modified":1671532297762},{"_id":"themes/landscape/layout/_partial/post/gallery.ejs","hash":"3d9d81a3c693ff2378ef06ddb6810254e509de5b","modified":1671532297762},{"_id":"themes/landscape/layout/_partial/post/tag.ejs","hash":"2fcb0bf9c8847a644167a27824c9bb19ac74dd14","modified":1671532297762},{"_id":"themes/landscape/layout/_partial/post/title.ejs","hash":"2f275739b6f1193c123646a5a31f37d48644c667","modified":1671532297762},{"_id":"themes/landscape/source/css/_extend.styl","hash":"222fbe6d222531d61c1ef0f868c90f747b1c2ced","modified":1671532297762},{"_id":"themes/landscape/source/css/_variables.styl","hash":"628e307579ea46b5928424313993f17b8d729e92","modified":1671532297762},{"_id":"themes/landscape/layout/_partial/archive-post.ejs","hash":"c7a71425a946d05414c069ec91811b5c09a92c47","modified":1671532297761},{"_id":"themes/landscape/source/fancybox/blank.gif","hash":"2daeaa8b5f19f0bc209d976c02bd6acb51b00b0a","modified":1671532297762},{"_id":"themes/landscape/source/fancybox/fancybox_loading.gif","hash":"1a755fb2599f3a313cc6cfdb14df043f8c14a99c","modified":1671532297762},{"_id":"themes/landscape/source/css/style.styl","hash":"a70d9c44dac348d742702f6ba87e5bb3084d65db","modified":1671532297762},{"_id":"themes/landscape/source/fancybox/fancybox_sprite.png","hash":"17df19f97628e77be09c352bf27425faea248251","modified":1671532297763},{"_id":"themes/landscape/source/fancybox/fancybox_sprite@2x.png","hash":"30c58913f327e28f466a00f4c1ac8001b560aed8","modified":1671532297762},{"_id":"themes/landscape/source/fancybox/jquery.fancybox.css","hash":"aaa582fb9eb4b7092dc69fcb2d5b1c20cca58ab6","modified":1671532297763},{"_id":"themes/landscape/source/fancybox/fancybox_loading@2x.gif","hash":"273b123496a42ba45c3416adb027cd99745058b0","modified":1671532297762},{"_id":"themes/landscape/source/fancybox/jquery.fancybox.pack.js","hash":"9e0d51ca1dbe66f6c0c7aefd552dc8122e694a6e","modified":1671532297763},{"_id":"themes/landscape/source/js/script.js","hash":"2876e0b19ce557fca38d7c6f49ca55922ab666a1","modified":1671532297762},{"_id":"themes/landscape/source/css/_util/grid.styl","hash":"0bf55ee5d09f193e249083602ac5fcdb1e571aed","modified":1671532297763},{"_id":"themes/landscape/source/css/_partial/article.styl","hash":"10685f8787a79f79c9a26c2f943253450c498e3e","modified":1671532297763},{"_id":"themes/landscape/source/fancybox/jquery.fancybox.js","hash":"d08b03a42d5c4ba456ef8ba33116fdbb7a9cabed","modified":1671532297763},{"_id":"themes/landscape/source/css/_partial/archive.styl","hash":"db15f5677dc68f1730e82190bab69c24611ca292","modified":1671532297763},{"_id":"themes/landscape/source/css/_partial/comment.styl","hash":"79d280d8d203abb3bd933ca9b8e38c78ec684987","modified":1671532297763},{"_id":"themes/landscape/source/css/_util/mixin.styl","hash":"44f32767d9fd3c1c08a60d91f181ee53c8f0dbb3","modified":1671532297763},{"_id":"themes/landscape/source/css/_partial/header.styl","hash":"85ab11e082f4dd86dde72bed653d57ec5381f30c","modified":1671532297763},{"_id":"themes/landscape/source/fancybox/fancybox_overlay.png","hash":"b3a4ee645ba494f52840ef8412015ba0f465dbe0","modified":1671532297762},{"_id":"themes/landscape/source/css/_partial/footer.styl","hash":"e35a060b8512031048919709a8e7b1ec0e40bc1b","modified":1671532297763},{"_id":"themes/landscape/source/css/_partial/sidebar-aside.styl","hash":"890349df5145abf46ce7712010c89237900b3713","modified":1671532297763},{"_id":"themes/landscape/source/css/_partial/mobile.styl","hash":"a399cf9e1e1cec3e4269066e2948d7ae5854d745","modified":1671532297763},{"_id":"themes/landscape/source/css/_partial/highlight.styl","hash":"bf4e7be1968dad495b04e83c95eac14c4d0ad7c0","modified":1671532297763},{"_id":"themes/landscape/source/css/_partial/sidebar.styl","hash":"404ec059dc674a48b9ab89cd83f258dec4dcb24d","modified":1671532297763},{"_id":"themes/landscape/source/css/_partial/sidebar-bottom.styl","hash":"8fd4f30d319542babfd31f087ddbac550f000a8a","modified":1671532297763},{"_id":"themes/landscape/source/css/fonts/FontAwesome.otf","hash":"b5b4f9be85f91f10799e87a083da1d050f842734","modified":1671532297764},{"_id":"themes/landscape/source/css/fonts/fontawesome-webfont.eot","hash":"7619748fe34c64fb157a57f6d4ef3678f63a8f5e","modified":1671532297764},{"_id":"themes/landscape/source/css/fonts/fontawesome-webfont.woff","hash":"04c3bf56d87a0828935bd6b4aee859995f321693","modified":1671532297764},{"_id":"themes/landscape/source/fancybox/helpers/fancybox_buttons.png","hash":"e385b139516c6813dcd64b8fc431c364ceafe5f3","modified":1671532297762},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-thumbs.css","hash":"4ac329c16a5277592fc12a37cca3d72ca4ec292f","modified":1671532297764},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-media.js","hash":"294420f9ff20f4e3584d212b0c262a00a96ecdb3","modified":1671532297764},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-thumbs.js","hash":"47da1ae5401c24b5c17cc18e2730780f5c1a7a0c","modified":1671532297764},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-buttons.css","hash":"1a9d8e5c22b371fcc69d4dbbb823d9c39f04c0c8","modified":1671532297764},{"_id":"themes/landscape/source/fancybox/helpers/jquery.fancybox-buttons.js","hash":"dc3645529a4bf72983a39fa34c1eb9146e082019","modified":1671532297764},{"_id":"themes/landscape/source/css/fonts/fontawesome-webfont.ttf","hash":"7f09c97f333917034ad08fa7295e916c9f72fd3f","modified":1671532297764},{"_id":"themes/landscape/source/css/fonts/fontawesome-webfont.svg","hash":"46fcc0194d75a0ddac0a038aee41b23456784814","modified":1671532297763},{"_id":"themes/landscape/source/css/images/banner.jpg","hash":"f44aa591089fcb3ec79770a1e102fd3289a7c6a6","modified":1671532297764},{"_id":"public/2022/08/26/药物前药、中间体和代谢产物的专利问题/index.html","hash":"62b0406568c41879747b443c9a3f710c9e8b41ac","modified":1672305118837},{"_id":"public/archives/index.html","hash":"4b30300f837eceb8fb560325e9e364c36a44c25b","modified":1672305118837},{"_id":"public/archives/2022/index.html","hash":"f6e8df79e0dc307b029994859428258264c5da56","modified":1672305118837},{"_id":"public/archives/2022/08/index.html","hash":"fa9d6b0d5ee13f14a8f9c39e8425ac4455501791","modified":1672305118837},{"_id":"public/index.html","hash":"df52e6f99ff9d71f312e9a6ed18bc856b8ae7182","modified":1672305118837},{"_id":"public/fancybox/fancybox_loading.gif","hash":"1a755fb2599f3a313cc6cfdb14df043f8c14a99c","modified":1672305118837},{"_id":"public/fancybox/blank.gif","hash":"2daeaa8b5f19f0bc209d976c02bd6acb51b00b0a","modified":1672305118837},{"_id":"public/fancybox/fancybox_loading@2x.gif","hash":"273b123496a42ba45c3416adb027cd99745058b0","modified":1672305118837},{"_id":"public/fancybox/fancybox_overlay.png","hash":"b3a4ee645ba494f52840ef8412015ba0f465dbe0","modified":1672305118837},{"_id":"public/fancybox/fancybox_sprite.png","hash":"17df19f97628e77be09c352bf27425faea248251","modified":1672305118837},{"_id":"public/fancybox/fancybox_sprite@2x.png","hash":"30c58913f327e28f466a00f4c1ac8001b560aed8","modified":1672305118837},{"_id":"public/css/fonts/fontawesome-webfont.eot","hash":"7619748fe34c64fb157a57f6d4ef3678f63a8f5e","modified":1672305118837},{"_id":"public/css/fonts/fontawesome-webfont.woff","hash":"04c3bf56d87a0828935bd6b4aee859995f321693","modified":1672305118837},{"_id":"public/fancybox/helpers/fancybox_buttons.png","hash":"e385b139516c6813dcd64b8fc431c364ceafe5f3","modified":1672305118837},{"_id":"public/css/fonts/FontAwesome.otf","hash":"b5b4f9be85f91f10799e87a083da1d050f842734","modified":1672305118837},{"_id":"public/fancybox/jquery.fancybox.css","hash":"aaa582fb9eb4b7092dc69fcb2d5b1c20cca58ab6","modified":1672305118837},{"_id":"public/js/script.js","hash":"2876e0b19ce557fca38d7c6f49ca55922ab666a1","modified":1672305118837},{"_id":"public/fancybox/helpers/jquery.fancybox-buttons.css","hash":"1a9d8e5c22b371fcc69d4dbbb823d9c39f04c0c8","modified":1672305118837},{"_id":"public/fancybox/helpers/jquery.fancybox-buttons.js","hash":"dc3645529a4bf72983a39fa34c1eb9146e082019","modified":1672305118837},{"_id":"public/fancybox/helpers/jquery.fancybox-media.js","hash":"294420f9ff20f4e3584d212b0c262a00a96ecdb3","modified":1672305118837},{"_id":"public/fancybox/helpers/jquery.fancybox-thumbs.css","hash":"4ac329c16a5277592fc12a37cca3d72ca4ec292f","modified":1672305118837},{"_id":"public/fancybox/helpers/jquery.fancybox-thumbs.js","hash":"47da1ae5401c24b5c17cc18e2730780f5c1a7a0c","modified":1672305118837},{"_id":"public/css/style.css","hash":"3986ef4b1f56bf0ac3bc45aab261e0278794c3f1","modified":1672305118837},{"_id":"public/fancybox/jquery.fancybox.pack.js","hash":"9e0d51ca1dbe66f6c0c7aefd552dc8122e694a6e","modified":1672305118837},{"_id":"public/fancybox/jquery.fancybox.js","hash":"d08b03a42d5c4ba456ef8ba33116fdbb7a9cabed","modified":1672305118837},{"_id":"public/css/fonts/fontawesome-webfont.ttf","hash":"7f09c97f333917034ad08fa7295e916c9f72fd3f","modified":1672305118837},{"_id":"public/css/fonts/fontawesome-webfont.svg","hash":"46fcc0194d75a0ddac0a038aee41b23456784814","modified":1672305118837},{"_id":"public/css/images/banner.jpg","hash":"f44aa591089fcb3ec79770a1e102fd3289a7c6a6","modified":1672305118837}],"Category":[],"Data":[],"Page":[],"Post":[{"_content":"## 定义探究\n\n**前药：**也称前体药物、药物前体、前驱药物等，是指药物经过化学结构修饰后得到的在体外无活性或活性较小、在体内经酶或非酶的转化释放出活性药物而发挥药效的化合物。[^1]\n\n**药物中间体：**用于药品合成工艺过程中的一些化工原料或化工产品。这种化工产品，不需要药品的生产许可证，在普通的化工厂即可生产，只要达到一些的级别，即可用于药品的合成。[^2]\n\n**药物代谢产物：**药物经体内药物代谢酶的作用后的产物。\n\n### 定义细节\n\n**前药的分类**\n\n前药可以分为载体前药和生物前药，载体前药是将活性药物结构和具有运输作用的化合物以共价键结合，进入体内以简单的水解作用分解的前药。大多数通过改变脂溶性来更好地进入体内。生物前药是通过人体内的酶进行氧化还原反应来改变自身结构得到活性化合物的前药。\n\n## 侵权问题\n\n### 案例介绍\n\n#### 诺华诉重庆新原兴案\n\n**案情简介**\n\n本案原告为诺华公司，其拥有一项名为“嘧啶衍生物及其制备方法和用途”的专利，保护的是伊马替尼及甲磺酸伊马替尼（格列卫）。被告是重庆新原兴药业有限公司。原告发现被告生产、销售和许诺销售了伊马替尼和甲磺酸伊马替尼，同时还生产、销售和许诺销售了哌嗪苯甲酸等用于制造伊马替尼的中间体。原告将被告诉至重庆市第一中级人民法院，请求判令原告就直接侵权和间接侵权承担停止侵权和赔偿损失的民事责任。\n\n本案一审经侵权对比明确了被告生产的伊马替尼、甲磺酸伊马替尼落入了原告专利权利要求的保护范围，构成专利直接侵权。\n\n针对间接侵权的起诉，被告主张涉案中间体除用于制造甲磺酸伊马替尼外尚具备其他商业用途，但并未举证证明。一审法院认为，新原兴公司并未举证证明，上述三种中间体除用于制备伊马替尼和甲磺酸伊马替尼外，还具有其他用途。新原兴公司出售该中间体必然导致买受人将其用于制造侵犯涉案专利的伊马替尼和甲磺酸伊马替尼产品；其次，新原兴公司在其网站上明确说明前述中间体为制造伊马替尼和甲磺酸伊马替尼的中间体，即新原兴公司对其行为必然导致前述后果是明知的。基于此，一审法院认定新原兴公司构成间接侵权。[^3]\n\n新原兴公司不服一审判决，并在二审中提交了证据，证明哌嗪苯甲酸还具有其他用途，并非专门用于制造伊马替尼和甲磺酸伊马替尼。对此，二审法院认为：根据新原兴公司在二审提供的证据，哌嗪苯甲酸或其盐酸盐曾经作为中间体用于合成某种已知药物的前药，具有其他用途。但即便如此，新原兴公司曾在其网站、书面宣传材料以及实际销售行为中明确将哌嗪苯甲酸作为甲磺酸伊马替尼的中间体进行许诺销售和销售，且直至二审审理期间才提供其他用途证据，也表明其在本案纠纷发生前并未意识到哌嗪苯甲酸尚具有其他用途，而是完全将其用于制造甲磺酸伊马替尼。因此，新原兴公司销售、许诺销售哌嗪苯甲酸就是为了诱导直接侵权的发生，从而构成对涉案专利的间接侵权。[^3]\n\n**法律分析**\n\n关于间接侵权，我国《专利法》并没有进行规定。人民法院往往依照民法典的共同侵权以及《最高人民法院关于审理侵犯专利权纠纷案件\n应用法律若干问题的解释（二）》进行判决。\n\n即便被告在二审中提出了哌嗪苯甲酸具有其他用途，但被告在网站、宣传和实际销售中明确了将其作为合成伊马替尼的中间体，具有“明知”的主观要件，存在“积极诱导”他人侵权的行为，因此构成间接侵权。\n\n#### 海他西林案\n\n本案原告为Beecham，被告为Bristol。原告拥有关于抗生素氨苄西林及其制造方法的英国专利，被告在英国销售海他西林。\n\n海他西林是氨苄西林的前药，在体内可以水解为氨苄西林。\n\n英国上议院指出，海他西林是氨苄西林的复制品（reproduction），尽管结构存在差异，但对本领域技术人员来说是一种非实质性改变。海他西林仍然落在专利权利保护范围之内。\n\n## 学习思考的问题\n\n### 中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题\n\n### 侵权判断问题\n\n直接侵权的界定和间接侵权的判断\n\n### 药品专利的布局\n\n\n\n[^1]: 尤启东.药物化学【M】北京：化学工业出版社，2015第二版：31-33\n[^2]:王镜岩 朱圣庚 徐长法．生物化学（第三版 上册）．北京：高等教育出版社，2002：6\n[^3]: http://www.chinaipmagazine.com/zl/ColumnView.asp?fId=80&id=194\n\n","source":"_posts/药物前药、中间体和代谢产物的专利问题.md","raw":"## 定义探究\n\n**前药：**也称前体药物、药物前体、前驱药物等，是指药物经过化学结构修饰后得到的在体外无活性或活性较小、在体内经酶或非酶的转化释放出活性药物而发挥药效的化合物。[^1]\n\n**药物中间体：**用于药品合成工艺过程中的一些化工原料或化工产品。这种化工产品，不需要药品的生产许可证，在普通的化工厂即可生产，只要达到一些的级别，即可用于药品的合成。[^2]\n\n**药物代谢产物：**药物经体内药物代谢酶的作用后的产物。\n\n### 定义细节\n\n**前药的分类**\n\n前药可以分为载体前药和生物前药，载体前药是将活性药物结构和具有运输作用的化合物以共价键结合，进入体内以简单的水解作用分解的前药。大多数通过改变脂溶性来更好地进入体内。生物前药是通过人体内的酶进行氧化还原反应来改变自身结构得到活性化合物的前药。\n\n## 侵权问题\n\n### 案例介绍\n\n#### 诺华诉重庆新原兴案\n\n**案情简介**\n\n本案原告为诺华公司，其拥有一项名为“嘧啶衍生物及其制备方法和用途”的专利，保护的是伊马替尼及甲磺酸伊马替尼（格列卫）。被告是重庆新原兴药业有限公司。原告发现被告生产、销售和许诺销售了伊马替尼和甲磺酸伊马替尼，同时还生产、销售和许诺销售了哌嗪苯甲酸等用于制造伊马替尼的中间体。原告将被告诉至重庆市第一中级人民法院，请求判令原告就直接侵权和间接侵权承担停止侵权和赔偿损失的民事责任。\n\n本案一审经侵权对比明确了被告生产的伊马替尼、甲磺酸伊马替尼落入了原告专利权利要求的保护范围，构成专利直接侵权。\n\n针对间接侵权的起诉，被告主张涉案中间体除用于制造甲磺酸伊马替尼外尚具备其他商业用途，但并未举证证明。一审法院认为，新原兴公司并未举证证明，上述三种中间体除用于制备伊马替尼和甲磺酸伊马替尼外，还具有其他用途。新原兴公司出售该中间体必然导致买受人将其用于制造侵犯涉案专利的伊马替尼和甲磺酸伊马替尼产品；其次，新原兴公司在其网站上明确说明前述中间体为制造伊马替尼和甲磺酸伊马替尼的中间体，即新原兴公司对其行为必然导致前述后果是明知的。基于此，一审法院认定新原兴公司构成间接侵权。[^3]\n\n新原兴公司不服一审判决，并在二审中提交了证据，证明哌嗪苯甲酸还具有其他用途，并非专门用于制造伊马替尼和甲磺酸伊马替尼。对此，二审法院认为：根据新原兴公司在二审提供的证据，哌嗪苯甲酸或其盐酸盐曾经作为中间体用于合成某种已知药物的前药，具有其他用途。但即便如此，新原兴公司曾在其网站、书面宣传材料以及实际销售行为中明确将哌嗪苯甲酸作为甲磺酸伊马替尼的中间体进行许诺销售和销售，且直至二审审理期间才提供其他用途证据，也表明其在本案纠纷发生前并未意识到哌嗪苯甲酸尚具有其他用途，而是完全将其用于制造甲磺酸伊马替尼。因此，新原兴公司销售、许诺销售哌嗪苯甲酸就是为了诱导直接侵权的发生，从而构成对涉案专利的间接侵权。[^3]\n\n**法律分析**\n\n关于间接侵权，我国《专利法》并没有进行规定。人民法院往往依照民法典的共同侵权以及《最高人民法院关于审理侵犯专利权纠纷案件\n应用法律若干问题的解释（二）》进行判决。\n\n即便被告在二审中提出了哌嗪苯甲酸具有其他用途，但被告在网站、宣传和实际销售中明确了将其作为合成伊马替尼的中间体，具有“明知”的主观要件，存在“积极诱导”他人侵权的行为，因此构成间接侵权。\n\n#### 海他西林案\n\n本案原告为Beecham，被告为Bristol。原告拥有关于抗生素氨苄西林及其制造方法的英国专利，被告在英国销售海他西林。\n\n海他西林是氨苄西林的前药，在体内可以水解为氨苄西林。\n\n英国上议院指出，海他西林是氨苄西林的复制品（reproduction），尽管结构存在差异，但对本领域技术人员来说是一种非实质性改变。海他西林仍然落在专利权利保护范围之内。\n\n## 学习思考的问题\n\n### 中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题\n\n### 侵权判断问题\n\n直接侵权的界定和间接侵权的判断\n\n### 药品专利的布局\n\n\n\n[^1]: 尤启东.药物化学【M】北京：化学工业出版社，2015第二版：31-33\n[^2]:王镜岩 朱圣庚 徐长法．生物化学（第三版 上册）．北京：高等教育出版社，2002：6\n[^3]: http://www.chinaipmagazine.com/zl/ColumnView.asp?fId=80&id=194\n\n","slug":"药物前药、中间体和代谢产物的专利问题","published":1,"date":"2022-08-26T07:05:19.085Z","updated":"2022-08-26T09:46:13.152Z","title":"","comments":1,"layout":"post","photos":[],"link":"","_id":"clc8vag1o0000bbkk3zwa0fux","content":"<h2 id=\"定义探究\"><a href=\"#定义探究\" class=\"headerlink\" title=\"定义探究\"></a>定义探究</h2><p><strong>前药：</strong>也称前体药物、药物前体、前驱药物等，是指药物经过化学结构修饰后得到的在体外无活性或活性较小、在体内经酶或非酶的转化释放出活性药物而发挥药效的化合物。<a href=\"%E5%B0%A4%E5%90%AF%E4%B8%9C.%E8%8D%AF%E7%89%A9%E5%8C%96%E5%AD%A6%E3%80%90M%E3%80%91%E5%8C%97%E4%BA%AC%EF%BC%9A%E5%8C%96%E5%AD%A6%E5%B7%A5%E4%B8%9A%E5%87%BA%E7%89%88%E7%A4%BE%EF%BC%8C2015%E7%AC%AC%E4%BA%8C%E7%89%88%EF%BC%9A31-33\">^1</a></p>\n<p><strong>药物中间体：</strong>用于药品合成工艺过程中的一些化工原料或化工产品。这种化工产品，不需要药品的生产许可证，在普通的化工厂即可生产，只要达到一些的级别，即可用于药品的合成。[^2]</p>\n<p><strong>药物代谢产物：</strong>药物经体内药物代谢酶的作用后的产物。</p>\n<h3 id=\"定义细节\"><a href=\"#定义细节\" class=\"headerlink\" title=\"定义细节\"></a>定义细节</h3><p><strong>前药的分类</strong></p>\n<p>前药可以分为载体前药和生物前药，载体前药是将活性药物结构和具有运输作用的化合物以共价键结合，进入体内以简单的水解作用分解的前药。大多数通过改变脂溶性来更好地进入体内。生物前药是通过人体内的酶进行氧化还原反应来改变自身结构得到活性化合物的前药。</p>\n<h2 id=\"侵权问题\"><a href=\"#侵权问题\" class=\"headerlink\" title=\"侵权问题\"></a>侵权问题</h2><h3 id=\"案例介绍\"><a href=\"#案例介绍\" class=\"headerlink\" title=\"案例介绍\"></a>案例介绍</h3><h4 id=\"诺华诉重庆新原兴案\"><a href=\"#诺华诉重庆新原兴案\" class=\"headerlink\" title=\"诺华诉重庆新原兴案\"></a>诺华诉重庆新原兴案</h4><p><strong>案情简介</strong></p>\n<p>本案原告为诺华公司，其拥有一项名为“嘧啶衍生物及其制备方法和用途”的专利，保护的是伊马替尼及甲磺酸伊马替尼（格列卫）。被告是重庆新原兴药业有限公司。原告发现被告生产、销售和许诺销售了伊马替尼和甲磺酸伊马替尼，同时还生产、销售和许诺销售了哌嗪苯甲酸等用于制造伊马替尼的中间体。原告将被告诉至重庆市第一中级人民法院，请求判令原告就直接侵权和间接侵权承担停止侵权和赔偿损失的民事责任。</p>\n<p>本案一审经侵权对比明确了被告生产的伊马替尼、甲磺酸伊马替尼落入了原告专利权利要求的保护范围，构成专利直接侵权。</p>\n<p>针对间接侵权的起诉，被告主张涉案中间体除用于制造甲磺酸伊马替尼外尚具备其他商业用途，但并未举证证明。一审法院认为，新原兴公司并未举证证明，上述三种中间体除用于制备伊马替尼和甲磺酸伊马替尼外，还具有其他用途。新原兴公司出售该中间体必然导致买受人将其用于制造侵犯涉案专利的伊马替尼和甲磺酸伊马替尼产品；其次，新原兴公司在其网站上明确说明前述中间体为制造伊马替尼和甲磺酸伊马替尼的中间体，即新原兴公司对其行为必然导致前述后果是明知的。基于此，一审法院认定新原兴公司构成间接侵权。[^3]</p>\n<p>新原兴公司不服一审判决，并在二审中提交了证据，证明哌嗪苯甲酸还具有其他用途，并非专门用于制造伊马替尼和甲磺酸伊马替尼。对此，二审法院认为：根据新原兴公司在二审提供的证据，哌嗪苯甲酸或其盐酸盐曾经作为中间体用于合成某种已知药物的前药，具有其他用途。但即便如此，新原兴公司曾在其网站、书面宣传材料以及实际销售行为中明确将哌嗪苯甲酸作为甲磺酸伊马替尼的中间体进行许诺销售和销售，且直至二审审理期间才提供其他用途证据，也表明其在本案纠纷发生前并未意识到哌嗪苯甲酸尚具有其他用途，而是完全将其用于制造甲磺酸伊马替尼。因此，新原兴公司销售、许诺销售哌嗪苯甲酸就是为了诱导直接侵权的发生，从而构成对涉案专利的间接侵权。[^3]</p>\n<p><strong>法律分析</strong></p>\n<p>关于间接侵权，我国《专利法》并没有进行规定。人民法院往往依照民法典的共同侵权以及《最高人民法院关于审理侵犯专利权纠纷案件<br>应用法律若干问题的解释（二）》进行判决。</p>\n<p>即便被告在二审中提出了哌嗪苯甲酸具有其他用途，但被告在网站、宣传和实际销售中明确了将其作为合成伊马替尼的中间体，具有“明知”的主观要件，存在“积极诱导”他人侵权的行为，因此构成间接侵权。</p>\n<h4 id=\"海他西林案\"><a href=\"#海他西林案\" class=\"headerlink\" title=\"海他西林案\"></a>海他西林案</h4><p>本案原告为Beecham，被告为Bristol。原告拥有关于抗生素氨苄西林及其制造方法的英国专利，被告在英国销售海他西林。</p>\n<p>海他西林是氨苄西林的前药，在体内可以水解为氨苄西林。</p>\n<p>英国上议院指出，海他西林是氨苄西林的复制品（reproduction），尽管结构存在差异，但对本领域技术人员来说是一种非实质性改变。海他西林仍然落在专利权利保护范围之内。</p>\n<h2 id=\"学习思考的问题\"><a href=\"#学习思考的问题\" class=\"headerlink\" title=\"学习思考的问题\"></a>学习思考的问题</h2><h3 id=\"中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题\"><a href=\"#中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题\" class=\"headerlink\" title=\"中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题\"></a>中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题</h3><h3 id=\"侵权判断问题\"><a href=\"#侵权判断问题\" class=\"headerlink\" title=\"侵权判断问题\"></a>侵权判断问题</h3><p>直接侵权的界定和间接侵权的判断</p>\n<h3 id=\"药品专利的布局\"><a href=\"#药品专利的布局\" class=\"headerlink\" title=\"药品专利的布局\"></a>药品专利的布局</h3><p>[^2]:王镜岩 朱圣庚 徐长法．生物化学（第三版 上册）．北京：高等教育出版社，2002：6<br>[^3]: <a href=\"http://www.chinaipmagazine.com/zl/ColumnView.asp?fId=80&amp;id=194\">http://www.chinaipmagazine.com/zl/ColumnView.asp?fId=80&amp;id=194</a></p>\n","site":{"data":{}},"excerpt":"","more":"<h2 id=\"定义探究\"><a href=\"#定义探究\" class=\"headerlink\" title=\"定义探究\"></a>定义探究</h2><p><strong>前药：</strong>也称前体药物、药物前体、前驱药物等，是指药物经过化学结构修饰后得到的在体外无活性或活性较小、在体内经酶或非酶的转化释放出活性药物而发挥药效的化合物。<a href=\"%E5%B0%A4%E5%90%AF%E4%B8%9C.%E8%8D%AF%E7%89%A9%E5%8C%96%E5%AD%A6%E3%80%90M%E3%80%91%E5%8C%97%E4%BA%AC%EF%BC%9A%E5%8C%96%E5%AD%A6%E5%B7%A5%E4%B8%9A%E5%87%BA%E7%89%88%E7%A4%BE%EF%BC%8C2015%E7%AC%AC%E4%BA%8C%E7%89%88%EF%BC%9A31-33\">^1</a></p>\n<p><strong>药物中间体：</strong>用于药品合成工艺过程中的一些化工原料或化工产品。这种化工产品，不需要药品的生产许可证，在普通的化工厂即可生产，只要达到一些的级别，即可用于药品的合成。[^2]</p>\n<p><strong>药物代谢产物：</strong>药物经体内药物代谢酶的作用后的产物。</p>\n<h3 id=\"定义细节\"><a href=\"#定义细节\" class=\"headerlink\" title=\"定义细节\"></a>定义细节</h3><p><strong>前药的分类</strong></p>\n<p>前药可以分为载体前药和生物前药，载体前药是将活性药物结构和具有运输作用的化合物以共价键结合，进入体内以简单的水解作用分解的前药。大多数通过改变脂溶性来更好地进入体内。生物前药是通过人体内的酶进行氧化还原反应来改变自身结构得到活性化合物的前药。</p>\n<h2 id=\"侵权问题\"><a href=\"#侵权问题\" class=\"headerlink\" title=\"侵权问题\"></a>侵权问题</h2><h3 id=\"案例介绍\"><a href=\"#案例介绍\" class=\"headerlink\" title=\"案例介绍\"></a>案例介绍</h3><h4 id=\"诺华诉重庆新原兴案\"><a href=\"#诺华诉重庆新原兴案\" class=\"headerlink\" title=\"诺华诉重庆新原兴案\"></a>诺华诉重庆新原兴案</h4><p><strong>案情简介</strong></p>\n<p>本案原告为诺华公司，其拥有一项名为“嘧啶衍生物及其制备方法和用途”的专利，保护的是伊马替尼及甲磺酸伊马替尼（格列卫）。被告是重庆新原兴药业有限公司。原告发现被告生产、销售和许诺销售了伊马替尼和甲磺酸伊马替尼，同时还生产、销售和许诺销售了哌嗪苯甲酸等用于制造伊马替尼的中间体。原告将被告诉至重庆市第一中级人民法院，请求判令原告就直接侵权和间接侵权承担停止侵权和赔偿损失的民事责任。</p>\n<p>本案一审经侵权对比明确了被告生产的伊马替尼、甲磺酸伊马替尼落入了原告专利权利要求的保护范围，构成专利直接侵权。</p>\n<p>针对间接侵权的起诉，被告主张涉案中间体除用于制造甲磺酸伊马替尼外尚具备其他商业用途，但并未举证证明。一审法院认为，新原兴公司并未举证证明，上述三种中间体除用于制备伊马替尼和甲磺酸伊马替尼外，还具有其他用途。新原兴公司出售该中间体必然导致买受人将其用于制造侵犯涉案专利的伊马替尼和甲磺酸伊马替尼产品；其次，新原兴公司在其网站上明确说明前述中间体为制造伊马替尼和甲磺酸伊马替尼的中间体，即新原兴公司对其行为必然导致前述后果是明知的。基于此，一审法院认定新原兴公司构成间接侵权。[^3]</p>\n<p>新原兴公司不服一审判决，并在二审中提交了证据，证明哌嗪苯甲酸还具有其他用途，并非专门用于制造伊马替尼和甲磺酸伊马替尼。对此，二审法院认为：根据新原兴公司在二审提供的证据，哌嗪苯甲酸或其盐酸盐曾经作为中间体用于合成某种已知药物的前药，具有其他用途。但即便如此，新原兴公司曾在其网站、书面宣传材料以及实际销售行为中明确将哌嗪苯甲酸作为甲磺酸伊马替尼的中间体进行许诺销售和销售，且直至二审审理期间才提供其他用途证据，也表明其在本案纠纷发生前并未意识到哌嗪苯甲酸尚具有其他用途，而是完全将其用于制造甲磺酸伊马替尼。因此，新原兴公司销售、许诺销售哌嗪苯甲酸就是为了诱导直接侵权的发生，从而构成对涉案专利的间接侵权。[^3]</p>\n<p><strong>法律分析</strong></p>\n<p>关于间接侵权，我国《专利法》并没有进行规定。人民法院往往依照民法典的共同侵权以及《最高人民法院关于审理侵犯专利权纠纷案件<br>应用法律若干问题的解释（二）》进行判决。</p>\n<p>即便被告在二审中提出了哌嗪苯甲酸具有其他用途，但被告在网站、宣传和实际销售中明确了将其作为合成伊马替尼的中间体，具有“明知”的主观要件，存在“积极诱导”他人侵权的行为，因此构成间接侵权。</p>\n<h4 id=\"海他西林案\"><a href=\"#海他西林案\" class=\"headerlink\" title=\"海他西林案\"></a>海他西林案</h4><p>本案原告为Beecham，被告为Bristol。原告拥有关于抗生素氨苄西林及其制造方法的英国专利，被告在英国销售海他西林。</p>\n<p>海他西林是氨苄西林的前药，在体内可以水解为氨苄西林。</p>\n<p>英国上议院指出，海他西林是氨苄西林的复制品（reproduction），尽管结构存在差异，但对本领域技术人员来说是一种非实质性改变。海他西林仍然落在专利权利保护范围之内。</p>\n<h2 id=\"学习思考的问题\"><a href=\"#学习思考的问题\" class=\"headerlink\" title=\"学习思考的问题\"></a>学习思考的问题</h2><h3 id=\"中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题\"><a href=\"#中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题\" class=\"headerlink\" title=\"中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题\"></a>中间体、前药或者代谢产物申请专利时新颖性、创造性的判断问题</h3><h3 id=\"侵权判断问题\"><a href=\"#侵权判断问题\" class=\"headerlink\" title=\"侵权判断问题\"></a>侵权判断问题</h3><p>直接侵权的界定和间接侵权的判断</p>\n<h3 id=\"药品专利的布局\"><a href=\"#药品专利的布局\" class=\"headerlink\" title=\"药品专利的布局\"></a>药品专利的布局</h3><p>[^2]:王镜岩 朱圣庚 徐长法．生物化学（第三版 上册）．北京：高等教育出版社，2002：6<br>[^3]: <a href=\"http://www.chinaipmagazine.com/zl/ColumnView.asp?fId=80&amp;id=194\">http://www.chinaipmagazine.com/zl/ColumnView.asp?fId=80&amp;id=194</a></p>\n"}],"PostAsset":[],"PostCategory":[],"PostTag":[],"Tag":[]}}